Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes

Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes - TENDERNESS

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012508

Enrollment

Registered

2013-12-06

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Teneligliptin 20 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who give written informed consent. 2.Outpatients 3.Patients who are on dieting and exercise therapy more than 12 weeks. 4.Patients whose HbA1c between 6.9% and 10.4%. 5.Difference in HbA1c between the starting day and last visit (4 weeks ago). 6. Patients with no history of receiving DPP-4 inhibitors. 7.Patients with FPG less than 180 mg/dl and HOMA-IR more than 2.0

Exclusion criteria

Exclusion criteria: 1.Patients who have type 1 diabetes and/or secondary diabetes (Cushing syndrome or acromegaly). 2.Contraindication for DPP-4 inhibitors 3.Patients who have heart failure (NYHA category 3-4) 4.Patients who are prone to QT prolongation. 5 Alcohol intake excess. 6.Patients who are pregnant or may be pregnant 7.History of myocardial infarction 8.Patients who have received GLP-1 receptor agonists

Design outcomes

Primary

Measure	Time frame
Postprandial serum soluble CD26/DPP-4 levels, DPP-4 activity, and plasma glucose	—

Countries

Japan

Contacts

Public ContactYoshimasa Aso

Dokkyo Medical University Department of Endocrinology and Metabolism

yaso@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026